Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes

GlycoMark(R) Blood Test Now Established to Provide Physicians with Vital Information Missed by Hemoglobin A1c Test to More Effectively Manage Patients with Diabetes NEW YORK and WINSTON-SALEM, N.C., July 17 /PRNewswire/ -- Toyota Tsusho America, Inc. (New York, NY) and...

Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017

...than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by nippon Kayaku) to treat the indication. The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avast...

Bausch & Lomb Japan Names Mitsuo Hirose as Chairman

...recently he was representative director and chairman of Pacific Golf Group International Holdings KK. Prior roles included serving as president of Dai nippon Printing Company's U.S. operations, and as a founder of corporate governance and ethics consultancy Maverick Japan Inc. In addition, Mr. Hirose ...

Stop Use of Word 'Leper'

...an, have signed the Appeal. Mr Sasakawa, who is also Chairman of the nippon Foundation, pointed out that "since an effective cure became available in t...o their believers and followers." Contact: Keiko Mori The nippon Foundation Tel: +81-3-6229-5131 e-mail: k_mori@ps.nippon-foundatio...

Nippon Life Benefits Partners with Best Doctors to Help Members Make More Informed Health Care Decisions

... Their Care NEW YORK, Jan. 12 /PRNewswire/ -- nippon Life Benefits, a leading provider of employee bene...able to existing and new employer group clients of nippon Life Benefits. "Best Doctors offers our plan ...a Hosoda, president and chief executive officer of nippon Life Benefits. "Helping members make informed dec...

Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding

...ll GI bleeding remains undiagnosed," said study lead author Shu Tanaka, MD, nippon Medical School, Tokyo, Japan. "Until now, there has been no in-depth analys...scopy." Patients and Methods This study examined 108 patients at the nippon Medical School, Tokyo, Japan from July 2003 to February 2007 who had been r...

P&G Recognizes Top Performing Suppliers

...ticularly to P&G's blades, razors and Duracell businesses; -- Jones Lang LaSalle of Chicago, Illinois providing facilities management services; -- nippon Shokubai of Tokyo, Japan providing absorbent gel material for P&G's diaper business; -- Novozymes of Bagsvaerd, Denmark is an enzyme supplier for P&...

Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses

...corporate headquarters where he served as Senior Vice President and President of Drug Delivery, and in Japan, where he held the position of President, nippon Becton Dickinson. He started his medical devices career in 1975 with Mallinckrodt Group, where he held sales and marketing positions of increasing res...

Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International

...onal, Inc., focuses on developing performance products for the equine, canine, and human markets. Novus is privately owned by Mitsui and Co., Ltd. and nippon Soda Co., Ltd. For more information visit http://www.novusint.com . Martek Biosciences Corporation (Nasdaq: MATK ) is a leader in the innovation an...

GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology

...e rises is a key objective of diabetes drug therapy. GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis,...

Nippon in Medical Technology

Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease

...osclerosis. It was selected for clinical development from a series of small molecule compounds available to Cerenis through a licensing agreement with nippon Chemiphar Co., Ltd. "CER-002 is a novel compound which has shown significant antiatherosclerotic properties in animal models even at low doses. The ...

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer

... was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, amrubicin has been marketed by nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer o...

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

...ts, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to nippon Kayaku, a key player in the Japanese oncology market. Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prost...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

...ts, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to nippon Kayaku, a key player in the Japanese oncology market. Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent pros...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

...profits from sales of the product in Japan. Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to nippon Kayaku, a key player in the Japanese oncology market. About Benign Prostatic Hyperplasia Benign prostatic hyperplasia (BPH) is a non-cancerous enl...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

... was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer o...

Nippon in Medical Products

Growth Hormone Binding Protein ELISA Test

Description:...276, 2002. Hansen TK et al. J Clin Endocrinol Metab 87 (10): 4691-4698, 2002. Baumann G J Pediatr Endocrinol Metab 15 (7): 959-961, 2002. Kaji H nippon Rinsho 60 (2): 306-312, 2002....
Company:Diagnostic Systems Laboratories, Inc.

Nippon in Biological News

Springer and the Physiological Society of Japan sign publishing agreement

...mphasis is on human and vertebrate physiology, comparative papers are also included. Dr. Yasuo Sakuma, head of the Department of Physiology at the nippon Medical School in Tokyo and Editor-in-Chief of The Journal of Physiological Sciences , said, "In the post-genome era, increasing interest is being de...

Nippon in Biological Technology

"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila

...siness plan to launch 8-10 new products each year, nippon Universal Pharmaceutical Co. Ltd., a subsidiary of... Japan generic market. In 2007, the group acquired nippon Universal, a small generic company which now spear...n Japan. With a focus on quality medicines, nippon Universal will be leveraging Zydus' capabilities i...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... 'Prostate-63' Tests II-79 Mylan Pharmaceuticals Obtains FDA Approval for Finasteride's ANDA II-79 Aeterna Zentaris Enters into Agreement with nippon Kayaku II-79 Progenics Pharmaceuticals Broadens Association with Seattle Genetics II-80 Diosynth and Dendreon Sign Multi-Year Commercial S...

AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners

...urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America a...

AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners

...urope in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by nippon Kayaku and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and...

Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

... Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, nippon Kayaku, and Hoffmann-La Roche). Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his leadership, in less than three years Ascenta was ...

Replidyne Announces Second Quarter 2008 Results From Operations

...inated its supply agreement with Asubio Pharma and nippon Soda Co., Ltd. (Nippon Soda) for production of far...mbursement of engineering costs of $0.6 million to nippon Soda in accordance with the terms of the agreements. Replidyne also paid nippon Soda $0.9 million for delay compensation under the...

Replidyne Terminates Faropenem Agreements

...s supply agreement of up to Japanese Yen 65 (approximately $0.6 million) to nippon Soda Co. Ltd. Replidyne will also pay nippon Soda Co. Ltd. Japanese Yen 99 million (approximately $0.9 million) for dela...

AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia

...s from sales of ozarelix in Japan. On July 26, 2006 AEterna Zentaris licensed the Japanese rights for all ozarelix potential oncology indications to nippon Kayaku, a key player in the Japanese oncology market. About Cetrorelix Cetrorelix pamoate is an investigational agent that has demonstrated in Pha...

Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

... KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced that nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking ma...

Martek Announces Fourth Quarter and FY 2007 Financial Results

...distributorship agreement for Martek's DHA Gold(R) animal feed product with Novus International, Inc, an affiliate of Mitsui and Co., Ltd. and nippon Soda Co., Ltd. Martek will serve as Novus's sole source supplier of DHA for all of its poultry and swine feed and enrichment products. All No...